EK-193

N/A

Report date: 2026/03/19 17:01:23

Base Information

Drug NameEK-193
Drug Alias NameEK-193
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsAnti-CD3
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Lvzhu Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Lvzhu Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A